CIK 0001520262 · Large accelerated filer
Alkermes plc.
Sign in to watch- Ticker
- ALKS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981007018
- Phone
- 00-353-1-772-8000
- Business address
- CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, Ireland, 00000
- Former names
- ANTLER SCIENCE TWO PLC, Antler Science Two Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,070,874
- in 5 filings, $1.1M under 10b5-1 plans
Net −$1,070,874. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-05 | Nichols Christian Todd SVP, Chief Commercial Officer | Shares withheld for taxes | −1,555 | $29.46 | $46K | 42,929 |
| 2023-06-05 | Nichols Christian Todd SVP, Chief Commercial Officer | Option exercise · Restricted Stock Unit Award | −3,500 | 0 | ||
| 2023-05-30 | Nichols Christian Todd SVP, Chief Commercial Officer | Option exercise 10b5-1 | +19,634 | $20.43 | $401K | 68,118 |
| 2023-05-30 | Nichols Christian Todd SVP, Chief Commercial Officer | Sale 10b5-1 | −27,134 | $28.93 | $785K | 40,984 |
| 2023-05-30 | Nichols Christian Todd SVP, Chief Commercial Officer | Option exercise · Employee Stock Option (Right to Buy) 10b5-1 | −19,634 | 44,327 | ||
| 2023-05-09 | Wysenski Nancy Director | Option exercise 10b5-1 | +35,000 | $31.13 | $1.1M | 50,829 |
| 2023-05-09 | Wysenski Nancy Director | Option exercise 10b5-1 | +6,250 | $31.13 | $195K | 57,079 |
| 2023-05-09 | Wysenski Nancy Director | Sale 10b5-1 | −41,250 | $31.24 | $1.3M | 15,829 |
| 2023-05-09 | Wysenski Nancy Director | Option exercise · Non Qualified Stock Option (Right to Buy) 10b5-1 | −35,000 | 0 | ||
| 2023-05-09 | Wysenski Nancy Director | Option exercise · Non Qualified Stock Option (Right to Buy) 10b5-1 | −6,250 | 0 | ||
| 2023-02-23 | POPS RICHARD F Director and CEO, Alkermes plc | Grant or award · Employee Stock Option (Right to Buy) | +284,873 | 284,873 | ||
| 2023-02-23 | Nichols Christian Todd SVP, Chief Commercial Officer | Grant or award · Employee Stock Option (Right to Buy) | +100,512 | 100,512 | ||
| 2023-02-23 | Nichols Christian Todd SVP, Chief Commercial Officer | Grant or award · Restricted Stock Unit Award | +25,128 | 25,128 | ||
| 2023-02-23 | LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc. | Grant or award · Employee Stock Option (Right to Buy) | +63,962 | 63,962 | ||
| 2023-02-23 | LANDINE MICHAEL J SVP, Corp Dev., Alkermes, Inc. | Grant or award · Restricted Stock Unit Award | +15,991 | 15,991 | ||
| 2023-02-23 | Jackson Blair Curtis EVP, Chief Operating Officer | Grant or award · Employee Stock Option (Right to Buy) | +137,062 | 137,062 | ||
| 2023-02-23 | Jackson Blair Curtis EVP, Chief Operating Officer | Grant or award · Restricted Stock Unit Award | +34,266 | 34,266 | ||
| 2023-02-23 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +120,615 | 120,615 | ||
| 2023-02-23 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | Grant or award · Restricted Stock Unit Award | +30,154 | 30,154 | ||
| 2023-02-23 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | Grant or award · Employee Stock Option (Right to Buy) | +120,615 | 120,615 |
Page 42 of 60 · 1,194 trades